

# **Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/A743E4851F2EN.html>

Date: April 2018

Pages: 68

Price: US\$ 3,500.00 (Single User License)

ID: A743E4851F2EN

## **Abstracts**

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H1 2018

### **SUMMARY**

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) -

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 2, 1, 2 and 5 respectively. Similarly, the universities portfolio in Unknown stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Fabry Disease.

The latest report Alpha Galactosidase A - Pipeline Review, H1 2018, outlays comprehensive information on the Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics, complete with analysis by indications, stage of

development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)

The report reviews Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha

D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) development landscape

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Overview

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Companies

Involved in Therapeutics Development

Amicus Therapeutics Inc

greenovation Biotech GmbH

iBio Inc

JCR Pharmaceuticals Co Ltd

Pharming Group NV

Protalix BioTherapeutics Inc

Sangamo Therapeutics Inc

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Drug Profiles

agalsidase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

agalsidase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

agalsidase beta biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATB-101 + migalastat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVRRD-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Alpha Galactosidase A for Fabry Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate GLA for Fabry Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

migalastat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOSS-AGAL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegunigalsidase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGN-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-920 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Dormant Products

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Discontinued Products

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Product Development Milestones

Featured News & Press Releases

Mar 22, 2018: Amicus Therapeutics Announces Approval of Galafold (Migalastat) for Fabry Disease in Japan

Feb 12, 2018: U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease

Jan 31, 2018: Protalix BioTherapeutics' pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration

Jan 29, 2018: Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold (migalastat) for Fabry Disease in Canada

Jan 29, 2018: Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium 2018

Jan 29, 2018: JCR to Present Data On JR-051 at the 14th Annual WORLD Symposium 2018

Jan 17, 2018: Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Spain

Dec 27, 2017: Protalix BioTherapeutics' PRX-102 Granted Orphan Drug Designation by the European Commission

Dec 20, 2017: Greenovation Biotech Reports Positive Clinical Data from the Phase 1 Safety Study for moss-aGal

Dec 19, 2017: JCR Signs MoU with the Grand Duchy of Luxembourg on the Leasing of Industrial Site

Dec 14, 2017: Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease

Nov 27, 2017: Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference

Nov 20, 2017: Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference

Nov 13, 2017: Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union

Oct 17, 2017: Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Amicus Therapeutics Inc, H1 2018  
Pipeline by greenovation Biotech GmbH, H1 2018  
Pipeline by iBio Inc, H1 2018  
Pipeline by JCR Pharmaceuticals Co Ltd, H1 2018  
Pipeline by Pharming Group NV, H1 2018  
Pipeline by Protalix BioTherapeutics Inc, H1 2018  
Pipeline by Sangamo Therapeutics Inc, H1 2018  
Dormant Projects, H1 2018  
Discontinued Products, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

Amicus Therapeutics Inc

greenovation Biotech GmbH

iBio Inc

JCR Pharmaceuticals Co Ltd

Pharming Group NV

Protalix BioTherapeutics Inc

Sangamo Therapeutics Inc

## I would like to order

Product name: Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/A743E4851F2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A743E4851F2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970